Loading...
RNXT logo

RenovoRx, Inc.NasdaqCM:RNXT Stock Report

Market Cap US$38.2m
Share Price
US$0.85
US$2.75
68.9% undervalued intrinsic discount
1Y-23.0%
7D-2.9%
Portfolio Value
​
View

RenovoRx, Inc.

NasdaqCM:RNXT Stock Report

Market Cap: US$38.2m

RenovoRx (RNXT) Stock Overview

A clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. More details

RNXT fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Trading at 99.7% below our estimate of its fair value

Earnings are forecast to grow 69.3% per year

Risk Analysis

Does not have meaningful revenue ($1M)

Shareholders have been diluted in the past year

Does not have a meaningful market cap ($38M)


RNXT Community Fair Values

Create Narrative

See what 23 others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

Top Community Narratives

RNXT logo
RenovoRx

Revolutionizing Cancer Treatment

A Precision Approach to Hard-to-Treat Cancers RenovoRx, Inc. (Nasdaq: RNXT), based in Mountain View, California, is a clinical-stage biopharma company taking a new approach to cancer treatment.
View narrative
US$4.2
FV
79.6% undervalued intrinsic discount
7.6k
users have viewed this narrative
17users have liked this narrative
3users have commented on this narrative
130users have followed this narrative
View all narratives

RenovoRx, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for RenovoRx
Historical stock prices
Current Share PriceUS$0.85
52 Week HighUS$1.45
52 Week LowUS$0.70
Beta1.0
1 Month Change-16.99%
3 Month Change-8.39%
1 Year Change-22.97%
3 Year Change-60.23%
5 Year Changen/a
Change since IPO-88.22%

Recent News & Updates

Recent updates

Analysis Article • Aug 16

Here's Why We're Watching RenovoRx's (NASDAQ:RNXT) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • May 26

RenovoRx (NASDAQ:RNXT) Is Revolutionizing Cancer Treatment

RenovoRx, Inc. (Nasdaq: RNXT), based in Mountain View, California, is a clinical-stage biopharma company taking a new approach to cancer treatment. Using its Trans-Arterial Micro-Perfusion (TAMP™) platform, the company aims to solve a major issue in cancer care: how to get strong doses of chemo directly to the tumor while avoiding harmful side effects throughout the body.
New Narrative • Apr 30

Revolutionizing Cancer Treatment

A small incision is made in the leg to insert the RenovoCath® system.
Seeking Alpha • Feb 05

RenovoRx: From Clinical Promise To Commercial Reality And Trading At A Significant Discount

Summary RenovoRx's innovative RenovoCath and TAMP platform show promising clinical data, extending pancreatic cancer survival rate 5 months and improving quality of life. The company’s market cap of $70M is undervalued compared to an intrinsic value of $243M, driven by early commercial traction and strategic partnerships. Leadership and advisory board bring extensive experience, enhancing RenovoRx's potential for successful commercialization and market expansion. Positive clinical data, physician demand, and a new reimbursement code accelerated RenovoCath sales by an estimated 2 years. Read the full article on Seeking Alpha
Analysis Article • Oct 26

We Think RenovoRx (NASDAQ:RNXT) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Mar 31

Is RenovoRx (NASDAQ:RNXT) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Dec 16

Companies Like RenovoRx (NASDAQ:RNXT) Could Be Quite Risky

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Aug 15

RenovoRx reports Q2 results

RenovoRx press release (NASDAQ:RNXT): Q2 Net Loss of $2.6M As of June 30, 2022, the company had cash and cash equivalents and short-term marketable securities of $10.8M.
Analysis Article • Aug 04

Is RenovoRx (NASDAQ:RNXT) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Jul 19

RenovoRx names new finance CFO

RenovoRx (NASDAQ:RNXT) appoints James Ahlers as CFO, effective July 15, 2022, and the addition of Ronald B. Kocak as VP and Controller. Mr. Ahlers replaces Christopher J. Lehman, who joined in connection with its IPO and is leaving to pursue a new business opportunity. Mr. Ahlers served as CFO of Intarcia Therapeutics and has held senior finance roles with Titan Pharmaceuticals and Ansan Pharmaceuticals.
Analysis Article • Mar 16

RenovoRx (NASDAQ:RNXT) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Nov 30

We Think RenovoRx (NASDAQ:RNXT) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Shareholder Returns

RNXTUS BiotechsUS Market
7D-2.9%1.0%1.1%
1Y-23.0%40.3%26.7%

Return vs Industry: RNXT underperformed the US Biotechs industry which returned 44.4% over the past year.

Return vs Market: RNXT underperformed the US Market which returned 25.4% over the past year.

Price Volatility

Is RNXT's price volatile compared to industry and market?
RNXT volatility
RNXT Average Weekly Movement9.2%
Biotechs Industry Average Movement10.7%
Market Average Movement7.2%
10% most volatile stocks in US Market16.2%
10% least volatile stocks in US Market3.1%

Stable Share Price: RNXT has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: RNXT's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200917Shaun Bagairenovorx.com

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.

RenovoRx, Inc. Fundamentals Summary

How do RenovoRx's earnings and revenue compare to its market cap?
RNXT fundamental statistics
Market capUS$38.23m
Earnings (TTM)-US$11.17m
Revenue (TTM)US$1.12m
34.3x
P/S Ratio
-3.4x
P/E Ratio

Is RNXT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RNXT income statement (TTM)
RevenueUS$1.12m
Cost of RevenueUS$327.00k
Gross ProfitUS$796.00k
Other ExpensesUS$11.96m
Earnings-US$11.17m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-0.25
Gross Margin70.88%
Net Profit Margin-994.48%
Debt/Equity Ratio0%

How did RNXT perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/14 06:52
End of Day Share Price 2026/05/14 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

RenovoRx, Inc. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Scott HenryAlliance Global Partners
Edward WooAscendiant Capital Markets LLC
Swayampakula RamakanthH.C. Wainwright & Co.